Literature DB >> 28238167

Effects of COX1-2/5-LOX blockade in Alzheimer transgenic 3xTg-AD mice.

Alessandra Bitto1, Daniela Giuliani2, Giovanni Pallio3, Natasha Irrera3, Eleonora Vandini2, Fabrizio Canalini2, Davide Zaffe4, Alessandra Ottani2, Letteria Minutoli3, Mariagrazia Rinaldi3, Salvatore Guarini2, Francesco Squadrito3, Domenica Altavilla5.   

Abstract

OBJECTIVE AND
DESIGN: Alzheimer's disease (AD) is associated with amyloid plaques (Aβ) and hyperphosphorylated tau protein tangles in the brain. We investigated the possible neuroprotective role of flavocoxid, a dual inhibitor of cyclooxygenases-1/2 (COX-1/2) and 5-Lipoxygenase (5-LOX), in triple-transgenic (3xTg-AD) mice.
SUBJECTS: Mice were 3 months at the beginning of the study. TREATMENT: Animals received once daily for 3-month saline solution or flavocoxid (20 mg/kg/ip).
METHODS: Morris water maze was used to assess learning and memory. Histology was performed to evidence Aβ plaques and neuronal loss, while inflammatory proteins were determined by western blot analysis.
RESULTS: Saline-treated 3xTg-AD mice showed an impairment in spatial learning and memory (assessed at 6 months of age), and increased expression of inflammatory and apoptotic molecules. Treatment of 3xTg-AD mice with flavocoxid reduced: (1) learning and memory loss; (2) the increased eicosanoid production and the phosphorylation level of amyloid precursor protein (APP-pThr668), Aβ 1-42, p-tau (pThr181), pERK, and the activation of the NLRP3 inflammasome; (3) Aβ plaques; and (4) neuronal loss, compared to saline-treated animals.
CONCLUSIONS: Pharmacological blockade of both COX-1/2 and 5-LOX was able to counteract the progression of AD by targeting pathophysiological mechanisms up- and downstream of Aβ and tau.

Entities:  

Keywords:  Alzheimer; Baicalin; Catechin; Memory; NLRP3; Neurodegeneration

Mesh:

Substances:

Year:  2017        PMID: 28238167     DOI: 10.1007/s00011-017-1022-x

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  39 in total

Review 1.  The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases.

Authors:  Frauke Zipp; Orhan Aktas
Journal:  Trends Neurosci       Date:  2006-08-01       Impact factor: 13.837

Review 2.  Cyclooxygenase-2 in synaptic signaling.

Authors:  Hongwei Yang; Chu Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

3.  NDP-α-MSH induces intense neurogenesis and cognitive recovery in Alzheimer transgenic mice through activation of melanocortin MC4 receptors.

Authors:  Daniela Giuliani; Laura Neri; Fabrizio Canalini; Anita Calevro; Alessandra Ottani; Eleonora Vandini; Paola Sena; Davide Zaffe; Salvatore Guarini
Journal:  Mol Cell Neurosci       Date:  2015-05-21       Impact factor: 4.314

4.  Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation.

Authors:  T Thomas; T G Nadackal; K Thomas
Journal:  Neuroreport       Date:  2001-10-29       Impact factor: 1.837

5.  A dual inhibitor of cyclooxygenase and 5-lipoxygenase protects against kainic acid-induced brain injury.

Authors:  Letteria Minutoli; Herbert Marini; Mariagrazia Rinaldi; Alessandra Bitto; Natasha Irrera; Gabriele Pizzino; Giovanni Pallio; Margherita Calò; Elena Bianca Adamo; Vincenzo Trichilo; Monica Interdonato; Federica Galfo; Francesco Squadrito; Domenica Altavilla
Journal:  Neuromolecular Med       Date:  2015-04-19       Impact factor: 3.843

Review 6.  Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease.

Authors:  Lars M Ittner; Jürgen Götz
Journal:  Nat Rev Neurosci       Date:  2010-12-31       Impact factor: 34.870

Review 7.  Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.

Authors:  Haythum O Tayeb; Hyun Duk Yang; Bruce H Price; Frank I Tarazi
Journal:  Pharmacol Ther       Date:  2011-12-16       Impact factor: 12.310

8.  EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP.

Authors:  Jamie Winderbaum Fernandez; Kavon Rezai-Zadeh; Demian Obregon; Jun Tan
Journal:  FEBS Lett       Date:  2010-09-17       Impact factor: 4.124

9.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

10.  Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity.

Authors:  Andis Klegeris; Patrick L McGeer
Journal:  Neurobiol Aging       Date:  2002 Sep-Oct       Impact factor: 4.673

View more
  13 in total

Review 1.  Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases.

Authors:  Maria Valeria Catani; Valeria Gasperi; Tiziana Bisogno; Mauro Maccarrone
Journal:  Antioxid Redox Signal       Date:  2017-07-24       Impact factor: 8.401

2.  Cyclooxygenase-2 Induced the β-Amyloid Protein Deposition and Neuronal Apoptosis Via Upregulating the Synthesis of Prostaglandin E2 and 15-Deoxy-Δ12,14-prostaglandin J2.

Authors:  Pei-Pei Guan; Yun-Yue Liang; Long-Long Cao; Xin Yu; Pu Wang
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

3.  Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF-κB signaling pathway.

Authors:  Xin Jin; Ming-Yan Liu; Dong-Fang Zhang; Xin Zhong; Ke Du; Ping Qian; Wei-Fan Yao; Hua Gao; Min-Jie Wei
Journal:  CNS Neurosci Ther       Date:  2019-01-24       Impact factor: 5.243

4.  Glial S100A6 Degrades β-amyloid Aggregation through Targeting Competition with Zinc Ions.

Authors:  Zhi-Ying Tian; Chun-Yan Wang; Tao Wang; Yan-Chun Li; Zhan-You Wang
Journal:  Aging Dis       Date:  2019-08-01       Impact factor: 6.745

Review 5.  A Novel Treatment Strategy by Natural Products in NLRP3 Inflammasome-Mediated Neuroinflammation in Alzheimer's and Parkinson's Disease.

Authors:  Jun Ho Lee; Hong Jun Kim; Jong Uk Kim; Tae Han Yook; Kyeong Han Kim; Joo Young Lee; Gabsik Yang
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 5.923

Review 6.  Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development.

Authors:  Kabir Ahluwalia; Brandon Ebright; Kingsley Chow; Priyal Dave; Andrew Mead; Roy Poblete; Stan G Louie; Isaac Asante
Journal:  Metabolites       Date:  2022-04-07

7.  Evidence for using a dual COX 1/2 and 5-LOX inhibitor in neurodegenerative diseases.

Authors:  Natasha Irrera; Alessandra Bitto
Journal:  Neural Regen Res       Date:  2017-07       Impact factor: 5.135

8.  A Selection of Important Genes and Their Correlated Behavior in Alzheimer's Disease.

Authors:  Yazeli E Cruz-Rivera; Jaileene Perez-Morales; Yaritza M Santiago; Valerie M Gonzalez; Luisa Morales; Mauricio Cabrera-Rios; Clara E Isaza
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 9.  Neuroprotective and Cognitive Enhancement Potentials of Baicalin: A Review.

Authors:  Kandhasamy Sowndhararajan; Ponnuvel Deepa; Minju Kim; Se Jin Park; Songmun Kim
Journal:  Brain Sci       Date:  2018-06-11

10.  The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice.

Authors:  Johanna Michael; Julia Zirknitzer; Michael Stefan Unger; Rodolphe Poupardin; Tanja Rieß; Nadine Paiement; Horst Zerbe; Birgit Hutter-Paier; Herbert Reitsamer; Ludwig Aigner
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.